Dyne Therapeutics: Pay

Dyne Therapeutics paid its one named executive on file $1.1M in FY2025 (Dec).

Pay$100 in the stock at the end of FY23 → $177
CEO pay is from each proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Pay of each named executive

John G. CoxPresident and Chief Executive Officer
FY2024 (Dec)
1 year
Douglas KerrChief Medical Officer
FY2024 (Dec)
1 year
Oxana BeskrovnayaChief Innovation Officer; Former Chief Scientific Officer
FY2024 (Dec)
FY2023 (Dec)Not disclosed
FY2022 (Dec)Not disclosed
3 years
Richard ScalzoFormer Senior Vice President, Head of Finance and Administration
FY2024 (Dec)
1 year
Johanna Friedl-NadererChief Commercial Officer
FY2025 (Dec)
FY2024 (Dec)
2 years

CEO pay against the pay peers

In FY2025 (Dec), the median CEO pay of the 14 peers with pay on file was $8.1M. CEO pay of Dyne Therapeutics for that year is not on file.

  1. 1BridgeBio Pharma
  2. 2Revolution Medicines
  3. 3Cytokinetics
  4. 4Immunovant
  5. 5IDEAYA Biosciences
  6. 6Xenon Pharmaceuticals
  7. 7Kymera Therapeutics
  8. 8CRISPR Therapeutics AG
  9. 9Arvinas
  10. 10Beam Therapeutics
  11. 11Celldex Therapeutics
  12. 12Intellia Therapeutics
  13. 13Denali Therapeutics
  14. 14Keros Therapeutics
  15. 15Dyne TherapeuticsNot disclosed
  16. 16ArcellxNot disclosed
  17. 17Crinetics PharmaceuticalsNot disclosed
  18. 18NuvalentNot disclosed
  19. 19Rocket PharmaceuticalsNot disclosed

Pay of each named executive comes from the Summary Compensation Table of each proxy statement. Realized pay adds the value of options used and stock that vested. CEO pay of each peer comes from its own Pay versus Performance table.